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SUMMARY
Both pro- and antioncogenic properties have been attributed to EphA2 kinase. We report that a possible
cause for this apparent paradox is diametrically opposite roles of EphA2 in regulating cell migration and inva-
sion. While activation of EphA2 with its ligand ephrin-A1 inhibited chemotactic migration of glioma and pros-
tate cancer cells, EphA2 overexpression promoted migration in a ligand-independent manner. Surprisingly,
the latter effects required phosphorylation of EphA2 on serine 897 by Akt, and S897A mutation abolished
ligand-independent promotion of cell motility. Ephrin-A1 stimulation of EphA2 negated Akt activation by
growth factors and caused EphA2 dephosphorylation on S897. In human astrocytoma, S897 phosphorylation
was correlated with tumor grades and Akt activation, suggesting that the Akt-EphA2 crosstalk may
contribute to brain tumor progression.INTRODUCTION
Chemotactic cell migration plays an important role in tumor inva-
sion by directing the spread of tumor cells toward growth
factors. Tumor cells can move while attached to each other,
which often occurs at early stage of cancer progression. During
malignant progression, tumor cells can undergo epithelial to
mesenchymal transition and adopt fibroblast-like cell migration
or amoeboid movement, by which they migrate as individual
cells (Friedl and Wolf, 2003). Although distinct in many aspects,different migration modes share similar signaling mechanisms.
Phosphoinositide 3-kinases (PI3Ks) and Rho family of GTPases
have been identified as key molecules in regulating cell migra-
tion. By generating PI(3,4,5)P3 at the proximity of chemoattrac-
tant, PI3Ks activity defines the leading edge of the migrating
cell (Charest and Firtel, 2006), whereas Rho GTPases regulate
the cytoskeletal reorganization that drives cell translocation
(Hall, 1998; Ridley et al., 2003; Charest and Firtel, 2007).
As a primary target of PI3Ks, Akt has well-documented roles in
promoting cell survival, proliferation, andgrowth (Engelmanet al.,SIGNIFICANCE
Akt is frequently activated in human glioblastoma and prostate cancer because of loss of PTEN or activation of components
in PI3K/Akt pathway. We report that EphA2 is both an upstream negative regulator and a downstream effector of Akt. Phos-
phorylation of EphA2 by Akt promotes cell migration and invasion. In contrast, EphA2 stimulation by ephrin-A1 ligand
suppresses Akt activation and inhibits cell migration. Thus, activation of PI3K/Akt pathway coupled with the loss of eph-
rin-As convert EphA2 from a tumor suppressor into a partner with Akt in promoting malignant progression. The data
have important implications in developing therapeutic strategies targeting EphA2 for treatment of malignant tumors where
PI3K/Akt pathway is activated.
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Shaw and Cantley, 2006). Recent cancer genome analyses re-
vealed Akt activation in vast majority of glioblastoma multiforme
(GBM) through inactivation of phosphatase/tensin homolog
deleted on chromosome 10 (PTEN), activation of receptor tyro-
sine kinases (RTKs), or amplification of Akt (TCGA Research
Network, 2008; Parsons et al., 2008). PTEN loss and Akt activa-
tion also frequently occur in human prostate cancer (Tomlins
et al., 2006). Increasing evidence shows that Akt signaling also
regulates migration of many types of cells (Kim et al., 2001; Ju
et al., 2007; Park et al., 2001; Meng et al., 2006; Shukla et al.,
2007; Vasko et al., 2004; Kim et al., 2005; Higuchi et al., 2001).
Akt has been proposed to modulate cell migration through
several mechanisms, including activation and recycling of
several integrins (Li et al., 2005; Somanath et al., 2007) and phos-
phorylation of an actin cross-linking protein Girdin at the cell
leading edge (Enomoto et al., 2005; Jiang et al., 2008).
The 16 members of vertebrate Eph kinases constitute the
largest subfamily of RTK superfamily. Interaction of Eph recep-
tors and their membrane-bound ligands, called ‘‘ephrins,’’ leads
to contact-dependent bidirectional signaling into the opposing
cells, which regulates diverse developmental and physiological
processes (Kullander and Klein, 2002; Miao and Wang, 2008;
Pasquale, 2008; Poliakov et al., 2004). Perturbation of Eph/eph-
rin systems has been documented in different types of human
cancer (Nakamoto and Bergemann, 2002; Pasquale, 2005;
Pasquale, 2008). The exact role of Eph kinase in tumor etiology
and progression has remained controversial. A case in point is
EphA2 kinase, which is among the most frequently affected
Eph kinases in human cancer. It is overexpressed in a variety
of human malignancies and is associated with poor prognosis
in several different tumor types, including GBM and cancers of
prostate, kidney, and lung (Ireton and Chen, 2005). In several
studies, overexpression of EphA2 has been linked to malignant
progression (Fang et al., 2005; Zelinski et al., 2001). Paradoxi-
cally, activation of EphA2 kinase on tumor cells can trigger
signaling events that are more consistent with a tumor
suppressor. Thus, ligand stimulation of EphA2 inhibits integrin
signaling, Ras/ERK pathway, and Rac GTPase activation, which
is correlated with inhibition of cell proliferation and migration
(Miao et al., 2000; Miao et al., 2001; Miao et al., 2003). Further-
more, EphA2 is found to be a target gene for p53 family of
proteins and causes apoptosis when overexpressed (Dohn
et al., 2001). Recent data also show that EphA2 is a key mediator
of UV-induced apoptosis independent of p53 (Zhang et al.,
2008). Further supporting a tumor suppressor role of EphA2,
we recently report dramatically increased susceptibility to skin
carcinogenesis in EphA2 KO mice (Guo et al., 2006). The seem-
ingly conflicting role of EphA2 kinase in the literature, either as an
oncoprotein or a tumor suppressor, is an outstanding dilemma in
cancer research today.
It is reported recently that EphA2 overexpression is frequently
accompanied by the loss of its cognate ligands (Dodelet and
Pasquale, 2000; Hafner et al., 2004; Wykosky et al., 2005; Ma-
crae et al., 2005). In human breast cancer and mouse skin
tumors, for example, there is an inverse relationship between
EphA2 and ephrin-A1 expression (Macrae et al., 2005; Guo
et al., 2006). This unbalanced expression pattern of EphA2 and
ligands led us to investigate whether the unligated EphA2 can10 Cancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc.be selected during tumor progression as the result of a pro-
oncogenic role.
RESULTS
Ligand-Independent Stimulation and Ligand-Dependent
Inhibition of Cell Migration by EphA2 Kinase
We investigated how EphA2 overexpression may regulate
chemotactic cell migration and invasion in the absence and pres-
ence of its ligand ephrin-A1 usingglioma cells as amodel system.
Examination of publicmicroarray database also revealed overex-
pression of EphA2 at mRNA levels in GBM (www.oncomine.org).
To mimic the in vivo situation, we overexpressed EphA2 in U373
glioma cells. Figure 1A shows that U373 cells express moderate
levels of endogenous EphA2 (Figure 1A), and infection with
EphA2-expressing retrovirus increased the level by about one
fold. In keeping with the lack of ligand expression, both endoge-
nous and ectopic EphA2 in U373 cells showed low basal activa-
tion. Stimulation with exogenous ephrin-A1 caused rapid EphA2
activation, which was followed by degradation of the receptor
itself, characteristic of most RTKs including Eph kinases.
Overexpression of EphA2 alone, in the absence of ligand stim-
ulation, significantly enhanced serum-inducedmigration of U373
cells in a Boyden chamber cell migration assay (Figure 1B). In
contrast, activation of EphA2 with its ligand ephrin-A1 signifi-
cantly inhibited the chemotaxis of both vector control and
EphA2-overexpressing cells. These data suggest that EphA2
has both ligand-independent stimulatory effects and ligand-
dependent inhibitory effects on chemotactic cell migration. The
diametrically opposite properties of EphA2 in regulating cell
migration were also observed in other cell types, including
HEK293, U87, A172, and PC-3M cells (see below).
In a reverse experiment, shRNA knocking down of EphA2
expression in U373 cells (Figure 1C) led to a significant reduction
in ligand-independent chemotaxis toward serum (Figure 1D). The
residual EphA2 on U373 cells was still able to mediate inhibition
of cell migration upon ligand stimulation (Figure 1D). Similarly,
shRNA knockdown of EphA2 in PC-3M prostate cancer cells
significantly reduced ligand-independent chemotaxis (Figures
1E and 1F), whereas overexpression of EphA2 promoted it (see
below).
Extensive previous investigations have established that
a major function of Eph kinases is the ligand-dependent repul-
sion of migrating cells and axons both in vitro and in vivo (Pas-
quale, 2005). Our data demonstrate that EphA2 receptor can
also promote cell migration in cooperation with growth factors
in a ligand-independent manner.
EphA2 Is Both a Substrate and a Negative Regulator
of Akt
In exploring the molecular mechanisms that mediate ligand-inde-
pendent promotion of chemotaxis byEphA2,wescreened several
signalingpathways.Among them, thePI3K/Aktpathwaystoodout
by robustly responding toserum inmigratingU373cells.Asshown
in Figure 1G, Akt became highly phosphorylated at both T308 and
S473 sites upon serum stimulation. Cotreatment with ephrin-A1
completely blocked Akt activation. To test possible direct cross-
talk between Akt and EphA2, we precipitated EphA2 and probed
it with an antibody recognizing the consensus Akt substrate sites
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Independent and Ligand-Dependent Func-
tions in Regulating Growth Factor-Induced
Chemotaxis
(A and B) Ectopic overexpression of EphA2
enhances serum-induced chemotaxis in a ligand-
independent manner. U373 cells were infected
with retroviral vector expressing EphA2 (pBabe-
puro-EphA2). Cells were stimulated with ephrin-
A1-Fc or Fc, and lysates were blotted for active
(p-EphA/B) or total EphA2 (A). The infected cells
were subjected to Boyden chamber cell migration
assay (B) with 5% FBS in lower chamber as che-
moattractant. Cell numbers from six random fields
were counted. Numbers represent mean ± SD.
***p < 0.001; ###p < 0.001.
(C–F) Down-regulation of EphA2 by shRNA
reduces serum-induced chemotaxis of U373 and
PC-3M cells. EphA2 shRNA or control GFP shRNA
was introduced into U373 (C and D) and PC-3M
cells (E and F) via Lentiviral infection (Open Biosys-
tems). Stable cell lines were subjected to immuno-
blot (C and E) or chemotactic cell migration assay
(D and F) as described for (A) and (B). Numbers
represent mean ± SD. **p < 0.01; ***p < 0.001;
##p < 0.01; ###p < 0.001.
(G and H) Serum stimulation results in S/T phos-
phorylation of EphA2 downstream fromAkt activa-
tion, which is inhibited by ephrin-A1 costimulation.
Serum-starved cells were scratch-wounded and
stimulated with FBS for the indicated times in
absence and presence of ephrin-A1-Fc. Total
cell lysates (G) or EphA kinase precipitates (H)
were subjected to immunoblot with the indicated
antibodies.
(I) Serum-induced EphA2 phosphorylation at Akt
substrate sites is abolished by pretreating cells
with LY294002. Experiments were performed as
described in (G) and (H) except that 10 mM of
LY294002 was added to the cells 1 hr prior to
serum stimulation.
(J) Serum-induced EphA2 phosphorylation at
Akt substrate sites is inhibited by DN-Akt. U373
cells that stably expressed DN-Akt or control vector were stimulated and analyzed as described in (G) and (H).
(K) EphA2 kinase activation by ephrin-A1 inhibits leading edge localization of phosphorylated Akt. Cells were starved and wounded as descried above.
After stimulation for 10 min with serum in the absence and presence of ephrin-A1-Fc, cells were fixed and stained with the indicated antibodies. Scale
bar, 25 mm.(Akt-pSub). The antibody detected a strong band at 125 kDa
on EphA2 precipitates prepared from serum-stimulated cells
(Figure 1H), indicating that EphA2 could be a substrate for Akt.
To confirm this unexpected finding, immunoprecipitation was
performed with Akt-pSub antibody, and the precipitates were
immunoblotted for EphA2. EphA2 could be readily detected in
the Akt-pSub immunoprecipitates (see Figure S1A available on-
line). Ephrin-A1 cotreatment led to complete inhibition of EphA2
phosphorylation at Akt substrate sites (Figure 1H), which corre-
lated with the abolishment of Akt activation (Figure 1G).
To verify the specificity of serum-induced S/T phosphorylation
of EphA2 to Akt activity, we performed the same experiments on
cells pretreated with PI3K inhibitor, LY294002. Inhibition of PI3K/
Akt pathway by LY294002 significantly reduced the phosphory-
lation of EphA2 at Akt substrate sites (Figure 1I). To further
demonstrate the Akt-EphA2 cross-talk, dominant negative (DN)
Akt was expressed in U373 cells. As shown in Figure 1J,serum-induced S/T phosphorylation of EphA2 was attenuated
by the expression of DN Akt. Taken together, these results iden-
tify a reciprocal regulatory loop between EphA2 and Akt, with
unligated EphA2 functioning as a downstream substrate and
effector of Akt kinase, but with the ligand-activated EphA2 func-
tioning as an upstream negative regulator to turn off Akt and
cause dephosphorylation of EphA2 at the Akt substrate site.
To examine where Akt-EphA2 cross-talk may take place in
migrating cells, we investigated the subcellular localization of
EphA2 relative to p-Akt. Figure 1K shows that under serum-
starved condition, p-Akt was low and uniformly distributed in
cells with no obvious colocalization with EphA2 (Figure 1K, top
panels). Within 10min after serum treatment, p-Akt was up-regu-
lated and became colocalized with EphA2 in lamellipodia at the
leading edge. Cotreatment with ephrin-A1 caused retraction of
lamellipodia and disappearance of p-Akt from the leading
edge. Akt-pSubwas also localized at themigrating front togetherCancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc. 11
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also present at high levels (Figure S1B), suggesting that Akt-
phosphorylated EphA2 is preferentially targeted to migrating
front. Thus, in response to growth factor stimulation, the unli-
gated EphA2 is phosphorylated at the leading edge by the active
Akt; upon addition of exogenous ligand, EphA2 is activated,
leading to ‘‘repulsion’’ of the migrating cells.
Serine 897 of EphA2 Is the Major Substrate Site for Akt
Sequence analysis of EphA2 revealed several potential S/T sites
that resemble the consensus motif of known Akt substrates
(Alessi et al., 1996; Manning and Cantley, 2007) (Figure 2A). To
map the Akt phosphorylation site(s) in EphA2, site-directed
mutagenesis was carried out to replace all five potential S/T resi-
dues with alanine in the cytoplasmic tail. A site in the ectodomain
(S479) was also included as a control. The resultant mutants
were initially tested in HEK293 cells. As we have reported previ-
ously, HEK293 cells express very low levels of endogenous
EphA2 (Miao et al., 2001), providing a low background to eval-
uate the mutants. In response to serum stimulation, cells ex-
pressing wild-type (WT)-EphA2 or EphA2 with single mutation
at S479, S636, T795, T838, and S910 were equally phosphory-
lated at Akt substrate sites. In contrast, S897A mutation
rendered EphA2 completely resistant to serum-induced phos-
phorylation at Akt substrate sites (Figure 2B). Identical results
were obtained from three independent transfections. Therefore,
our studies mapped serine 897 as the major site for Akt kinase
phosphorylation in EphA2. Structurally, serine 897 is located in
the linker region between EphA2 kinase domain and sterile
a motif (SAM), which is likely to be exposed and accessible to
Akt phosphorylation.
Figure 2. Serine 897 of EphA2 Is the Major Substrate Site
for Akt Activity, which Is Essential for Ligand-Indepen-
dent Promotion of Cell Migration
(A) Schematic illustration of relative positions of putative Akt
substrate sites in EphA2 cytoplasmic tail.
(B) S897A mutation abolishes serum-induced S/T phosphoryla-
tion of EphA2. HEK293 cells were infected with retroviral vectors
expressing WT or mutant EphA2. EphA kinases were precipitated
and immunoblotted for Akt-pSub and total EphA2.
(C) Immunofluorescence staining of infected HEK293 cells
shows that the exogenous EphA2 receptors were homogeneously
expressed. Scale bar, 25 mm.
(D) Both S897A and S897D mutations completely abolish the
serum-induced phosphorylation of EphA2 on Akt substrate sites.
Cells were stimulated and analyzed as described in B.
(E) Overexpression of WT-EphA2 but not S897A-EphA2 or S897D-
EphA2 enhances serum-stimulated cell migration. Cell migration
assay was performed as described in Figure 1. Numbers repre-
sent mean ± SD. ***p < 0.001.
Akt-Mediated Serine 897 Phosphorylation
Is the Major Mechanism Responsible
for Ligand-Independent Stimulation
of Cell Migration by EphA2
To determine the functional significance of phosphor-
ylation at S897, HEK293 cells expressingWT-, S897A-
EphA2 or control vector were characterized. A phos-
phomimetic mutation was also created by replacing
S897 with aspartic acid (S897D) and tested. Immunofluores-
cence and biochemical analysis showed that the exogenous
WT-, S897A-, and S897D-EphA2 were homogenously overex-
pressed in HEK293 cells (Figures 2C and 2D). Similar to what
we observed in U373 glioma cells (Figure 1B), overexpression
of WT-EphA2 increased serum-induced chemotaxis of HEK293
cells (Figure 2E). Interestingly, both S897A and S897Dmutations
completely abolished the cell migration-promoting effect by
EphA2 (Figure 2E). These results suggest that Akt phosphoryla-
tion of S897-EphA2 is largely responsible for the ligand-indepen-
dent stimulation of cell motility by EphA2 in HEK293 cells. The
fact that phosphomimetic mutation (S897D) had the same
effects as S897A indicates that phosphorylation, but not the
negative charge-induced conformational change, is needed to
promote cell migration.
Catalytic Activity of EphA2 Is Required for Ligand-
Dependent Inhibition, but Not for Ligand-Independent
Promotion of Cell Migration
To investigate the role of the intrinsic tyrosine kinase activity of
EphA2, a kinase-deficient EphA2 with D739N mutation was
tested in HEK293 cells. The mutant was still fully capable of
simulating chemotaxis toward serum when overexpressed
(Figure S2). However, it lost the ligand-dependent inhibition of
cell migration. Thus, the intrinsic catalytic activity of EphA2 is
required for ligand-dependent inhibition but not ligand-indepen-
dent promotion of cell migration. These and additional data
described below show that the two processes are mutually
exclusive and involve distinct signaling mechanisms. In the
context of ligand-independent promotion of cell migration,
EphA2 is serving as a substrate of Akt kinase when and if its12 Cancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc.
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distinct, the term ‘‘kinase’’ will be avoided when ligand-indepen-
dent functions of EphA2 are under discussion.
Ligand-Independent Promotion of Cell Migration
by EphA2 in Glioma and Prostate Cancer Cells
Requires S897 Phosphorylation and Is Sensitized
by PTEN Deletion
Next we investigated the effects of S897A on ligand-indepen-
dent chemotaxis in a panel of human tumor cell lines, including
U373, U87, A172, LN229, and T98G glioma cells, as well as
PC-3M prostate cancer cells. As expected, the PTEN null
U373, U87, and A172 cells generally had more active Akt than
did PTEN- WT T98G and LN229 cells (Figure S3). Hyperactive
Akt was also observed in the PTEN null PC-3M cells
(Figure S4) as well as in parental PC-3 cells (Shukla et al.,
2007). WT- and S897A-EphA2 were introduced into these cells
via retroviral infection (Figures 3A and 3B). Overexpression of
WT-EphA2 enhanced serum-stimulated chemotaxis compared
to vector control in PTEN null U373, U87, A172, and PC-3M cells
(Figures 3C and 3D). S897A mutation blocked most of the stim-
Figure 3. Serum-InducedChemotaxis in Glioma andProstate
Cancer Cells Is Dependent on Akt-Mediated Phosphorylation
of EphA2 at S897
(A and B) Overexpression of WT-EphA2 and S897A-EphA2 in the indi-
cated cell lines following retroviral infection.
(C andD) Chemotaxis toward serumwas promoted by overexpression
ofWT-EphA2 but not S897A-EphA2 in PTEN null tumor cells. Numbers
represent mean ± SD from 6 random fields. *p < 0.05; **p < 0.01;
***p < 0.001.
(E–H) Restoration of PTEN expression in PTEN-null U373 cells in-
hibited basal cell migration. PTEN re-expression significantly reduced
FBS-induced Akt activities (E), which was quantified in panel F. In both
Boyden chamber migration (G) and scratch wound (H) assays, PTEN
restoration reduced cell migration. Numbers represent mean ± SD
from 6 random fields. Scale bar, 100 mm.
ulatory effects in these cells. Interestingly, U373 cells ex-
pressing S897A-EphA2 displayed lower basal levels of
serum-induced chemotaxis than did vector control cells.
The seemingly dominant negative effects were not
observed in U87, A172, and PC-3M cells. The differences
may reflect the cell type-specific signaling networks regu-
lating chemotaxis.
Together, these data indicate that PTEN null cells with
hyperactive Akt may have become more dependent on
Akt-EphA2 cross-talk to promote cell motility. To test this
possibility, we restored PTEN expression in U373 cells,
which caused a significant reduction in serum-induced
Akt activities (Figures 3E and 3F). In both chemotactic
cell migration and scratch wound assays, restoration of
PTEN expression dramatically inhibited cell migration
(Figures 3G and 3H), supporting important roles of PTEN
loss in promoting malignant behaviors of glioma cells.
However, other mechanisms in addition to loss of PTEN
may also permit EphA2 to promote chemotactic cell
migration, since in PTEN-WT HEK293 cells, EphA2 over-
expression was still capable of promoting migration
(Figure 2E). Notably, hyperactivation of Akt can be
achieved by a variety of mechanisms including loss of PTEN,
RTK amplification/mutation, Akt amplification, and Ras activa-
tion. Further studies are needed to identify the alternative mech-
anisms.
Serum-Induced Glioma Cell Invasion through MatriGel
Also Requires Akt Phosphorylation of EphA2 on S897
Invasion through the surrounding normal tissues is a hallmark of
malignant progression, which is particularly deadly for glioma
patients. We used U87, U373, and A172 cell lines to test how
EphA2 might regulate serum-induced glioma cell invasion. The
multiplicity of the cell lines with a shared genetic alteration in
PTEN status makes them good models for assessing general
applicability ofour findings.We found that, in theabsenceof ligand
stimulation, overexpression of WT-EphA2 strongly promoted
MatriGel invasion by all three cell lines (Figures 4A–4C, open
bars). The S897A mutation largely abolished the stimulatory
effects. Together with the data from the last section, we conclude
thatEphA2 functions asa ligand-independent positive regulator of
chemotactic migration as well as invasion, and Akt-mediated
phosphorylation of EphA2 on S897 is required for both effects.Cancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc. 13
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Invasion by EphA2 Is Not Affected by S897A Mutation
Next we investigated whether S897 of EphA2 is involved in
ligand-dependent inhibition of cell migration and invasion.
Similar to what was found in U373 cells (Figure 1B), chemotactic
migration of A172 and U87 cells expressing WT-EphA2 or vector
control was significantly inhibited by ephrin-A1 (Figures 4D–4F).
Interestingly, S897A EphA2 was still capable of mediating eph-
rin-A1-induced inhibition of migration in all three cell lines,
despite its ability to abolish most ligand-independent promotion
of cell migration. Indeed, the degrees of ligand-dependent inhi-
bition were indistinguishable between WT- and S897A-EphA2
cells. Similarly, ephrin-A1 treatment also significantly blocked
MatriGel invasion of cells expressing either WT- or S897A-
EphA2 (Figures 4A–4C). One consistent difference across all
three cell lines was that both ligand-independent promotion
and ligand-dependent inhibition were more pronounced in the
invasion assay than migration assay (Figures 4A–4F).
Time-lapse imaging was employed to monitor morphology
and chemokinetic movement of cells on two-dimensional culture
plate. In keeping with the increased cell motility, U373 cells
expressing WT-EphA2 displayed elongated and polarized
morphology with a large protruding lamellipodium (Figure 4G)
and were more motile than vector control cells (Supplementary
Figure 4. EphA2 Promotes MatriGel Invasion, and S897A
Mutation Does Not Affect Ligand-Dependent Inhibition
of Cell Migration and Invasion
(A–C) EphA2 promotes MatriGel invasion in a ligand-independent
manner, which is abolished by S897A mutation (open bars).
(A–F) S897A mutation of EphA2 does not affect ligand-dependent
inhibitory effect on migration or invasion of U373, U87, and A172
cells. In both migration and invasion assays, 5% FBS was used
as chemoattractant. Numbers represent mean ± SD from 6
random fields. *p < 0.05, **p < 0.01, and ***p < 0.001 compared
to Fc control of the same cell line. ##p < 0.01 and ###p < 0.001
compared to Fc control of vector cells.
(G) Overexpression of WT-EphA2 induces a polarized morphology
and enhanced chemokinetic motility, which is inhibited by S897A
mutation. Cells were plated at low density in 6-well dishes and
subjected to time-lapse analysis. The still images at 0 and
360 min are shown. Arrows indicate cells that have gained net
translocation. Scale bar, 50 mm.
Movies). In contrast, cells expressing S897A-EphA2
showed a ‘‘pancake-like’’ morphology in culture
dishes and were largely stationary during the course
of the observation. Ephrin-A1 treatment minimized
chemokinetic movement in all three cell types.
Multiple Growth Factors Stimulate S897
Phosphorylation of EphA2
To better understand the function of S897 phosphory-
lation of EphA2, we generated and characterized
a rabbit polyclonal antibody against a synthetic phos-
phopeptide surrounding S897. We validated the spec-
ificity of the antibody in HEK293 cells expressing
WT- or S897A-EphA2. Immunoblot of total cell lysates
with the antibody detected a strong band at the same
molecular weight as EphA2 in the serum-stimulated
WT-EphA2-expressing cells, but not in cells expressing S897A-
EphA2 (Figure 5A). Costimulationwith serumandephrin-A1 abol-
ished the phospho-S897 (pS897)-EphA2 signal. A robust pS897
band comigrating with EphA2was also detected in EphA2 immu-
noprecipitates (Figure 5B). Conversely, EphA2 was detected in
the materials precipitated with the anti-pS897-EphA2 antibody
(Figure S5). Treatment of cell lysates with recombinant S/T
protein phosphatase 2A (PP2A) caused dephosphorylation of
pS897-EphA2 (Figure 5C). Finally, treatment of cells with SH-5,
an Akt inhibitor, suppressed S897 phosphorylation (Figure S6A),
as did LY294002, an inhibitor of PI3K (Figure S6B). Taken
together, this series of experiments confirmed specificity of the
antibody. Moreover, the results further established EphA2 as an
effector molecule for PI3K/Akt signaling cascade.
To determine which growth factors induce phosphorylation
of EphA2 on S897, we stimulated U373 glioma cells with a panel
of growth factors, including EGF, bFGF, PDGF, and HGF, all of
which have been implicated in human GBM. Serum was used
as a positive control. We found that all growth factors were
capable of inducing pS897-EphA2, which was correlated with
Akt activation (Figure 5D). In cell migration assays, all four growth
factors were potent chemoattractants for U373 cells (Figure 5E).
The number of migrating cells correlated with the degree of S897
phosphorylation and Akt activation. Costimulation of cells with14 Cancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc.
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S897 Phosphorylation of EphA2, which Is Re-
quired for EphA2 Localization to the Leading
Edge and for Cell Polarization
(A and B) Characterization of a rabbit polyclonal anti-
body against S897 phosphopeptide. Serum-starved
HEK293 cells that express vector, WT-EphA2, or
S897A-EphA2 were stimulated with FBS in the
absence and presence of ephrin-A1-Fc for 10 min.
Total cell lysates (A) and EphA kinase precipitates (B)
were analyzed by immunoblotting with polyclonal
anti-pS897-EphA2 and total EphA2.
(C) PP2A treatment causes dephosphorylation of
serum-induced pS897-EphA2. Serum-stimulated
U373 cell lysates were subjected to PP2A phospha-
tase assay followed by immunoblot with polyclonal
anti-pS897-EphA2.
(D and E) Multiple growth factors induce S897 phos-
phorylation of EphA2 and migration.
(D) Serum-starved U373 cells were stimulated with
10ng/ml of EGF, bFGF,PDGF,HGF, 10%FBS, or 10mM
LPA alone or in combination with Fc or ephrin-A1-Fc
for 10 min. Total cell lysates were analyzed as in (A).
(E) U373 cell migration toward same concentrations of
growth factors and LPA or 5% FBS. Numbers repre-
sent mean ± SD from 6 random fields. The numbers
over solid bars show the percentage of inhibition by
ephrin-A1.
(F) Inhibition of FGFR is not sufficient for inhibiting
serum-induced pS897-EphA2. Serum-starved U373
cells were pretreated with 10 mM SU5402 or 100 nM
1-(2-Amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyr-
imidin-7-yl)-3-tert-butyl urea (BU) for 30 min. Cells
were then stimulated with FBS for 10 min. Cell lysates
were analyzed by immunoblotting with polyclonal anti-
pS897-EphA2 and pS473-Akt.
(G) Phospho-S897-EphA2 is localized to the leading
edge and the tips of actin stress fibers. Serum-starved
cells were treated and processed for immunofluores-
cent staining as described in Figure 1K. Scale bars:
25 mm, top and bottom rows; 10 mm, zoomed images.
(H) Cells expressing mutant S897A-EphA2 show
defective cell polarization, which was correlated with
mislocalization of the mutant proteins to cell-cell junc-
tions. Scale bar, 25 mm.ephrin-A1-Fc significantly inhibited all growth factor-induced
pS897-EphA2 and chemotaxis, concomitant with Akt inactiva-
tion (Figures 5D and 5E). The degree of ephrin-A1-dependent
inhibition of Akt varied among different growth factors, with
strongest inhibition for bFGF; significant but less inhibition was
seen with EGF and HGF (Figures 5D and 5E). These results
suggest that phosphorylation of EphA2 at S897 is a common
mediator of growth factor-induced cell migration, which could
have important implications in understanding the molecular
basis of malignant progression for GBM and other tumor types.
LPA in serum is known to activate Akt and induce cell migra-
tion. However, in U373 cells, LPA is a weaker inducer of Akt
activation and chemotactic cell migration, which was not
affected by ephrin-A1 (Figures 5D and 5E). Thus, LPA in serum
did not contribute significantly to either Akt activation or S897
phosphorylation in this system.
Next we examined whether kinase activities of the growth
factor receptors are required for activation of Akt and phosphor-
ylation of EphA2 on S897. Two inhibitors of FGFR abolished thestimulatory effects of bFGF (Figure 5F). Although a small
decrease was observed, serum-induced activation of Akt and
pS897-EphA2 was not significantly reduced by FGFR inhibitors
(Figure 5F), consistent with the presence of multiple growth
factors in serum.
S897 Phosphorylation of EphA2 Is Required
for Dendritic Actin Cytoskeleton Assembly
and Lamellipodia Formation at the Leading Edge
of Migrating Cells
Immunofluorescence staining of U373 expressing WT-EphA2
revealed that pS897-EphA2 was localized to the migrating front
with dendritic actin in lamellipodia or tips of F-actin fibers that ran
perpendicular to the wound (Figure 5G). As expected, cells ex-
pressing mutant S897A-EphA2 showed little staining for phos-
pho-S897 (Figure 5G, lower panel). Staining for total EphA2
showed that the mutant S897A-EphA2 was primarily localized
to the cell-cell junctions instead (Figure 5H). Interestingly, prom-
inent actin stress fibers were detected in cells expressingmutantCancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc. 15
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EphA2 and Akt Crosstalk in Tumor InvasionFigure 6. Levels of pS897-EphA2 in Human Glioma Spec-
imens Are Correlated with Tumor Grades and Overlap
with Active Akt
(A–D) Rabbit polyclonal anti-pS897-EphA2 specifically recognizes
pS897-EphA2 in GBM specimens. Paraffin sections from a human
astrocytoma were stained with the anti-pS897-EphA2 antibody
preincubated with vehicle control (A), phospho-S897 peptide
(B), or unphosphorylated S897 peptide (C). Sections processed
with omission of primary antibody served as the negative control
(D). Scale bar, 50 mm.
(E–F) Normal brains were negative for pS897-EphA2. Scale bars:
200 mm in (E); 100 mm in (F).
(G–J) Grade I (G and H) and grade III (I and J) astrocytomas
showed low immunoreactivity for pS897-EphA2. Scale bars:
100 mm in (G) and (I); 50 mm in (H) and (J).
(K–T) Grade IV astrocytomas (or GBM) frequently showed high
levels of pS897-EphA2.
(K) Positive tumor cells localized to a necrotic area indicated by
an asterisk (K; scale bar, 100 mm). High power inset (L; scale bar,
10 mm) shows membrane expression pattern of pS897-EphA2.
(M and N) Perivascular staining pattern of pS897-EphA2. (N), inset
from (M). Scale bars: 200 mm in (M); 50 mm in (N). Blood vessels are
indicated by arrows.
(O) pS897-EphA2 was detected abundantly at the interface
between necrosis (asterisk) and vasculature (arrow). Scale bar,
100 mm.
(P) pS897-EphA2 was present at high levels in the meningeal inva-
sion. Positive tumor cells (Tu) invaded meninges (Me) and further
infiltrated the molecular layer of adjacent side of the gyrus (Mo).
Scale bar, 50 mm.
(Q–S) pS897-EphA2 was detected in the pseudopalisading cells
surrounding necrotic foci (asterisk indicates necrosis). R shows
the high power inset from (Q). Scale bar: 100 mm in (Q) and (S);
50 mm in (R).
(T) S897 phosphorylation of EphA2 was also abundant in micro-
vasculature proliferation, another distinguishing feature of GBM.
Scale bar, 50 mm.
(U–X) Phospho-S473-Akt expression in GBM. pS473-Akt was
most abundant in tumor cells surrounding blood vessels (V and W) or necrotic regions (X) where pS897-EphA2 presented at high levels. DV, dead vessel; LV,
live vessel. Asterisk indicates necrosis. Scale bars: 100 mm in (U), (V), and (X); 50 mm in (W).S897A-EphA2 that ran parallel to thewound (Figures 5G and 5H).
This is analogous to rearrangement of F-actin following stimula-
tion with ephrin-A1, which caused F-actin to switch from
a predominantly dendritic pattern in lamellipodia to stress fibers
that aligned with the direction of wounding (Figure S7). These
results suggest that phosphorylation of EphA2 at S897 by Akt
is critical for EphA2 localization at cell leading edge, which is
required to promote assembly of actin cytoskeleton and exten-
sion of lamellipodia.
In Human Astrocytoma, S897 Phosphorylation
of EphA2 Is Correlated with Malignant Progression
and Overlaps with Active Akt
PI3K/Akt is activated in the vast majority of human GBM (TCGA
Research Network, 2008; Parsons et al., 2008), and glioma cells
induced to migrate are known to have further elevated Akt activ-
ities (Joy et al., 2003). We hypothesize that if Akt phosphorylation
of S897-EphA2 facilitates glioma cell migration in vitro, S897
phosphorylation of EphA2 could be elevated during malignant
progression of human brain tumors. To test this, we performed
immunohistochemical (IHC) staining on paraffin-embedded
sections from normal human brains and human gliomas of
different grades using the phosphospecific antibody character-16 Cancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc.ized above. We first tested the specificity of the antibody in
IHC staining. The antibody detected pS897 signals in a grade
IV GBM. On adjacent sections, the signal was blocked by the
immunizing phosphopeptide but not the unphosphorylated
peptide (Figures 6A–6D), suggesting that the antibody specifi-
cally recognized p897-EphA2 in tumor sections.
As shown in Figures 6E and 6F, normal brains from five individ-
uals were largely negative for pS897-EphA2, whereas one case
of grade I (Figures 6G and 6H) and two cases of grade III astro-
cytomas (Figures 6I and 6J) showed low-to-moderate pS897-
EphA2 levels. In contrast, 19 of 21 cases of grade IV astrocy-
tomas (GBM) samples contained regions displaying high levels
of pS897-EphA2 (Figures 6K–6T). The areas affected varied
among different tumors, comprising 5% to over 90% of the non-
necrotic regions. The 90% positive rate is consistent with a
recent large scale study where Akt is activated in 88% of human
GBM cases (TCGA Research Network, 2008).
Interestingly the strongest staining for pS897-EphA2 was
frequently localized in regions known to be enriched for growth
factors and invasive cells in grade IV astrocytomas or GBM.
Clusters of strongly positive tumors cells were often observed
next to necrotic areas, one of the WHO-designated hallmarks
of grade IV astrocytomas (Figure 6K) (Miller and Perry, 2007;
Cancer Cell
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pS897-EphA2 could be visualized in the high magnification
images (Figure 6L). Phospho-S897-EphA2 was also abundantly
detected in the perivascular regions (Figures 6M and 6N), or at
the interface between vasculature and necrosis (Figure 6O).
Invasive glioma cells often migrate along blood vessels, which
is referred to as perivascular satellitosis, one of morphological
signatures of invasive GBM collectively known as Scherer’s
secondary structures (Scherer, 1938; Furnari et al., 2007). Phos-
pho-S897-EphA2 was also detected in a tumor that has infil-
trated meninges adjacent to normal brain (Figure 6P), further
supporting its role in promoting tumor cell migration. On multiple
sections, pS897-EphA2 was found at high levels in cells
comprising palisading necrosis (Figures 6Q–6S). In GBMs,
necrotic foci are often surrounded by pseudopalisading cells,
which are thought to be actively migrating and are critical for
tumor progression (Brat et al., 2004; Wippold et al., 2006).
Finally, pS897-EphA2 was found in microvascular proliferation
resulting from active angiogenesis in GBM (Figure 6T), suggest-
ing that pS897-EphA2 could also play a role in promoting endo-
thelial cell migration and invasion during neo-angiogenesis.
One prediction based on our data is that pS897-EphA2 and
pS473-Akt are likely to reside in the same cells in vivo. To directly
examine this possibility, we stained the same set of GBM spec-
imens for pS473-Akt. Interestingly, in most regions where there
was strong pS473-Akt, there was also robust staining for
pS897-EphA2 on adjacent sections (Figures 6V–6X). The spatial
colocalization was most pronounced in tumor cells surrounding
blood vessels (Figures 6V and 6Won adjacent slideswith Figures
6M and 6N) or necrotic regions (Figure 6X). In about a third of the
specimens, pS473-Akt signal was detectable but much weaker
than pS897-EphA2, possibly because of the more labile nature
of the pS473-Akt epitope, suggesting that p897-EphA2 could
serve as surrogate marker for Akt activation. Taken together,
the results demonstrate that phosphorylation of EphA2 at S897
Figure 7. A Model Depicting Ligand-Dependent Inhibition and
Ligand-Independent Stimulation of Cell Migration and Invasion
by EphA2
(A) In the absence of ligand, EphA2 is a substrate of Akt activated in tumor cells
due to growth factor receptor activation or loss of PTEN. EphA2 phosphory-
lated on S897 promotes cell polarization, lamellipodium protrusion, and cell
migration. S897A mutant of EphA2 is sufficient to block chemotactic cell
migration.
(B) Ephrin-A1 stimulation causes tyrosine phosphorylation in the juxtamem-
brane domain and serine dephosphorylation on S897 of EphA2, which
prevents lamellipodium protrusion and inhibits cell migration.by Akt is correlated with malignant progression of human astro-
cytoma. We propose that the cross-talk between RTK/PI3K/Akt
and EphA2 may contribute to malignant progression of glioma
and potentially other types of human cancers.
DISCUSSION
We report here that EphA2 kinase has diametrically opposite
roles in regulating chemotactic cell migration: ligand-indepen-
dent promotion and ligand-dependent inhibition. A reciprocal
regulatory loop between EphA2 and Akt was characterized
whereby unligated EphA2 is a substrate for Akt, which, in turn,
is negatively regulated by the ligand-activated EphA2 (see
Figure 7). We further demonstrate that phosphorylation of a
single serine residue, S897, by Akt is responsible for ligand-inde-
pendent promotion of cell migration and invasion by EphA2, and
the site becomes dephosphorylated upon ligand stimulation.
The ligand-dependent inhibition and ligand-independent stimu-
lation of cell migration and invasion may represent one possible
mechanism responsible for the hitherto conflicting roles attrib-
uted to EphA2 in tumorigenesis. Our data also suggest that
EphA2 is an important effector molecule of Akt in promoting
malignant progression, making it an attractive target for thera-
peutic intervention.
To Phosphorylate or to Dephosphorylate: S897
of EphA2 as a Binary Switch to Control Cell Motility
In addition to the well-characterized tyrosine phosphorylation
events, proteomic analyses in vitro and in vivo demonstrate
extensive serine/threonine phosphorylation of Eph kinases as
well (Kalo and Pasquale, 1999; Kalo et al., 2001). However,
neither the responsible kinases nor the physiological relevance
for any of the phospho-S/T sites has been documented. We
present cellular, biochemical, pharmacological, and patholog-
ical evidence to demonstrate that EphA2 is an unexpected
substrate for Akt S/T kinase in vitro and in vivo. The phosphory-
lation occurs predominantly if not exclusively at a single residue
S897. It is rapidly induced upon stimulation with serum and all
growth factors tested, suggesting that EphA2 serves as a
common downstream effector molecule for growth factor
signaling. The propensity of EphA2 to serve as a substrate for
Akt is dictated by the presence or absence of its cognate ligands.
In fact, ligand stimulation of EphA2 caused rapid dephosphory-
lation of phospho-S897 concomitant with dephosphorylation
and inactivation of Akt kinase. The reciprocal cross-talk with
RTK/PI3K/Akt pathway established in these studies adds
another layer of intricacy to EphA2 kinase signaling. Moreover,
it intimately interconnects EphA2 with one of the central nodes
of cell signaling network. Through the PI3K/Akt pathway,
EphA2 becomes an integral part of the large cellular signaling
network both as a substrate and as a negative regulator.
S897 of EphA2 is located in a linker region between the kinase
and SAM domains. Sequence alignments show that the linker is
not well conserved among different Eph kinases. The putative
recognition sequence for Akt is only conserved between
EphA2 (RLPS897TS) and EphA1 (RLPS906LS) kinases. In all other
mammalian Eph kinases, the amino acid corresponding to S897
is replaced by aspartic or glutamic acid, except for EphB6 and
EphA8. EphB6 does have a threonine; however, the requisiteCancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc. 17
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placedwith a leucine. EphA8 has a unique SAM linker completely
different from that of EphA2. Therefore, only EphA1 and EphA2
can serve as substrates for Akt at this site. First cloned from an
erythropoietin-producing hepatoma cell line in 1987, EphA1
was the namesake and founding member of Eph kinases (Hirai
et al., 1987). It will be interesting to determine whether EphA1
can indeed serve as a substrate for Akt, and how the phosphor-
ylating event may contribute to cell migration/invasion and
malignant transformation. The lack of the consensus sequence
in other 12 mammalian Eph kinases indicates that EphA1 and
EphA2 are functionally distinct. At a minimum, the differences
could limit the role of other Eph kinases in promoting cell migra-
tion and invasion in cooperation with PI3K/Akt pathway.
A Model for Ligand-Dependent Tumor Suppressive and
Ligand-Independent Pro-Oncogenic Functions of EphA2
As reviewed in the Introduction, an outstanding paradox in Eph
field is whether EphA2 is an oncogene or a tumor suppressor
gene. Upon examination of previous studies and the data herein,
a model emerges for both anti- and pro-oncogenic functions for
EphA2. We propose that the ligand-dependent inhibition of cell
proliferation and migration by EphA2 may help maintain homeo-
stasis in normal tissues and suppress tumor development at
early stages of tumorigenesis (Miao and Wang, 2008). On the
other hand, ligand-independent stimulation of cell migration by
EphA2 promotes tumor progression and fulfills an oncogenic
function by partnering with the activated Akt. Consistent with
this model, 22 of 29 breast cancer-derived cell lines have lost
EphA2 expression, compared with a relatively normal breast
epithelial cell line MCF10A, suggesting a tumor suppressor func-
tion of EphA2 in breast epithelial cells (Macrae et al., 2005). In the
remaining seven cell lines that still retain EphA2 expression, eph-
rin-A1 expression is invariably lost, leading to a loss of ligand-
dependent tumor suppressor functions. Moreover, the unligated
EphA2 can be hijacked by PI3K/Akt pathway frequently acti-
vated in breast cancer to promote malignant progression.
EphA2-Akt Crosstalk in Brain Tumors
and Its Clinical Implications
GBM is the most common primary brain tumor (Miller and Perry,
2007; Furnari et al., 2007). Its dismal prognosis with an average
14-month survival is attributable to difficulties in early detection
and to widespread brain invasion at the time of diagnosis. Exten-
sive molecular studies have identified PI3K/Akt signaling
cascade as one of the most frequently altered pathways in
primary and secondary GBM (Li et al., 1997; Wang et al., 2004;
TCGA Research Network, 2008; Parsons et al., 2008). Activation
of upstream RTK growth factor receptors and/or loss of the
negative regulator, PTEN, are themajor causes for PI3K/Akt acti-
vation, particularly in primary GBM. The data reported here show
that one pathological consequence of Akt activation is promo-
tion of glioma cell migration and invasion through phosphoryla-
tion of EphA2. Given that both EphA2 overexpression and Akt
activation occur in majority of human GBM, the Akt-EphA2
signaling axis could play a significant role in the malignant
progression of glioma in vivo.
The stable immunoreactivity of S897-EphA2 and its correlation
with tumor grades in human cancer suggest that it can be used18 Cancer Cell 16, 9–20, July 7, 2009 ª2009 Elsevier Inc.as an easy-to-detect marker for malignant tumor progression.
Moreover, because inhibitors of growth factor receptors, PI3K,
and Akt could all diminish pS897-EphA2, it may serve as a surro-
gate marker of measuring therapeutic efficacy for agents target-
ing various components in the RTK/Ras/PI3K/Akt pathway.
Finally, it is important to note that the intrinsic tyrosine kinase
activity of EphA2 is not required for its effects on promoting cell
migration. Therefore, tyrosine kinase inhibitors targeting EphA2,
either by design or by off-target effects, will not inhibit tumor cell
migration stimulated by the Akt-EphA2 axis. Moreover, such
inhibitors may have untoward side effects by inadvertently sup-
pressing the intrinsic tumor suppressor activities of EphA2. We
propose that targeting EphA2 kinase with agonists may consti-
tute more attractive therapeutic strategies, which will inhibit
malignant progression by suppressing Akt activation, severing
pro-oncogenic Akt phosphorylation of EphA2 and reactivating
its intrinsic tumor suppressor functions.
EXPERIMENTAL PROCEDURES
Reagents and Cell Culture
Ephrin-A1-Fc was produced as described elsewhere (Miao et al., 2000).
Rabbit polyclonal anti-pS473-Akt, anti-pT308-Akt, anti-Akt, and anti-Akt-pS/
T-substrates (Akt-pSub) were obtained from Cell Signaling. Rabbit anti-
pEphA/B was raised against the conserved phosphopeptides from the juxta-
membrane regions. Rabbit polyclonal phospho-S897-specific antibody was
raised against phosphopeptide DPRVSIRLP-pS897-TSGSEGVPFR. Other anti-
bodies were purchased from Santa Cruz Biotechnology (rabbit polyclonal
anti-EphA2) and Upstate Biotechnology (mouse monoclonal anti-EphA2).
LY294002, SU5402, FGFR inhibitor (1-(2-Amino-6-(3,5-dimethoxyphenyl)pyr-
ido[2,3-d]pyrimidin-7-yl)-3-tert-butyl urea), and Akt inhibitor II (SH-5) were
purchased from Calbiochem. Mutant EphA2 was generated using the Quick-
Change Kit (Stratagene). HEK293, U87, U373, LN229, A172, and T98G cells
weremaintained in Dulbecco’smodifiedMEMmedium (DMEM) supplemented
with 10% FBS, 10 mg/ml glutamate, 100 U/ml penicillin, and 0.1 mg/ml strep-
tomycin. PC-3M cells were maintained in RPMI-1640 supplemented with the
same supplements.
Cell Migration
Chemotactic cell migration was carried out as described elsewhere (Miao
et al., 2003). Briefly, both sides of the filter were coated with 10 mg/ml rat tail
collagen type I at 4Covernight; 13 105 cells in serum-freemedium containing
0.1% BSA were plated in the top of insert. Ephrin-A1-Fc or Fc was added to
a final concentration of 1 mg/ml to the lower chamber together with 5% FBS
or various growth factors. Cells were allowed to migrate for 4 hr and then fixed
with 4% paraformaldehyde. After staining with 0.5% crystal violet, cells that
have passed through the filter and stayed on the undersides of inserts were
counted. Time-lapse imaging was performed as described elsewhere (Miao
et al., 2005).
MatriGel Invasion Assay
Growth factor-reduced MatriGel-coated Transwell inserts (BD Biosciences)
were rehydrated with DMEM for 2 hr at 37C; 2.5 3 104 cells were plated in
the upper chamber. Ephrin-A1-Fc or Fc was added to the lower chamber con-
taining 5% FBS in DMEM. After incubation at 37C for 16–20 hr, cells were
fixed and stained with 0.5% crystal violet. Cells migrating through the MatriGel
and the pores of the filter were counted from six randomly selected fields.
Cell Stimulation, Immunoprecipitation, and Immunoblot
For stationary cells, subconfluent cells were stimulated with 1 mg/ml ephrin-
A1-Fc for different times. To study the signaling events in migrating cells, the
monolayer of freshly confluent cells was wounded by repeated scratch-
wounding using a multichannel pipette. Four hours after wounding, cells
were stimulated with 1 mg/ml ephrin-A1-Fc for different times. To evaluate
the serum-induced signaling, cells were starved in serum-free medium
Cancer Cell
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were stimulated with 10% FBS in the presence of 1 mg/ml Fc or ephrin-A1-Fc.
Immunoprecipitation and immunoblot were performed as described else-
where (Miao et al., 2000).
Immunohistochemistry
Studies involving human tissues from normal brain and astrocytomas were
approved by the Institutional Review Boards at MetroHealth Medical Center
and Case Western Reserve University. Paraffin-embedded sections were de-
paraffinized and rehydrated. Antigens were retrieved by boiling sections in
citrate buffer (pH 6.0) for 10 min. The endogenous peroxidase was blocked
with 3% H2O2. Sections were blocked with 5% normal goat serum and were
incubated with rabbit polyclonal anti-pS897-EphA2 (1:500) or anti-pS473-
Akt (1:50) at RT for 1–2 hr. After extensive washing in TBST, sections were
detected with biotinylated goat anti-rabbit secondary antibody for 30 min fol-
lowed by amplification with ABC reagents (Vectastain), and were visualized
with 3,30-diaminobenzidine. Sections were counterstained with hematoxylin.
To test the binding specificity of the rabbit polyclonal anti-pS897-EphA2, the
antibody was preincubated with 100 mM phospho-S897 peptide or unphos-
phorylated S897 peptide at RT for 1 hr. IHC staining was performed using
untreated or peptide-treated anti-pS897-EphA2 antibodies. A negative control
was obtained by omitting primary antibody.
Themicewere cared for in accordancewith guidelines set forth by the Amer-
ican Association for Accreditation of Laboratory Animal Care and the USPHS
‘‘Policy on Human Care and Use of Laboratory Animals,’’ and all studies were
approved and supervised by The Case Western Reserve University Institu-
tional Animal Care and Use Committee.
SUPPLEMENTAL DATA
Supplemental Data include eight figures and six movies and can be found with
this article online at http://www.cell.com/cancer-cell/supplemental/S1535-
6108(09)00143-3.
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